This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Adding abiraterone to standard treatment provides a lasting survival benefit for men whose prostate cancer has already spread at diagnosis, reinforcing the value of early treatment intensification. The findings come from almost eight years of follow-up in the academically led phase 3 PEACE-1 trial presented at the ESMO Congress 2026.

For men with de novo metastatic castration-sensitive prostate cancer (mCSPC), treatment is based on androgen deprivation therapy (ADT) to lower testosterone. Adding docetaxel chemotherapy or a second-generation hormonal therapy, such as abiraterone, improves survival, with a direct comparison finding no significant difference in overall survival between the two doublet regimens.

The PEACE-1 trial included 1,173 men with de novo mCSPC. All received standard of care (ADT, with or without docetaxel chemotherapy) and were randomly assigned to receive no additional treatment, abiraterone plus prednisone, radiotherapy to the prostate, or both abiraterone plus prednisone and radiotherapy. Overall, 57% had high-volume disease, indicating more extensive cancer spread. An earlier analysis showed that adding abiraterone to standard of care improved overall survival.

After a median follow-up of 7.7 years, adding abiraterone reduced the risk of death by 25% (hazard ratio [HR] 0.75; 95% confidence interval [CI] 0.65–0.87; p=0.0001). Median overall survival was 6.1 years with abiraterone versus 4.6 years without it.

82). 1% of men were alive at eight years.

Source link